14,451 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Acquired by Callan Family Office LLC

Callan Family Office LLC purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, Holdings Channel.com reports. The fund purchased 14,451 shares of the medical equipment provider’s stock, valued at approximately $7,543,000.

Other institutional investors have also recently bought and sold shares of the company. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter valued at $26,000. BankPlus Trust Department bought a new stake in Intuitive Surgical during the 4th quarter worth about $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Intuitive Surgical in the 4th quarter valued at about $31,000. MidAtlantic Capital Management Inc. bought a new position in shares of Intuitive Surgical in the third quarter worth about $33,000. Finally, Decker Retirement Planning Inc. acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $36,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

ISRG stock opened at $538.57 on Friday. The business has a 50-day moving average of $571.70 and a 200-day moving average of $530.95. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The stock has a market capitalization of $191.83 billion, a P/E ratio of 84.02, a P/E/G ratio of 5.85 and a beta of 1.43.

Analyst Upgrades and Downgrades

ISRG has been the subject of several research reports. Bernstein Bank lifted their target price on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Barclays lifted their price objective on Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. Citigroup upped their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Morgan Stanley upgraded shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $522.00 to $650.00 in a research report on Monday, December 2nd. Finally, CICC Research started coverage on shares of Intuitive Surgical in a research note on Monday, January 27th. They set a “neutral” rating and a $550.00 price target for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 270 shares of Intuitive Surgical stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $540.15, for a total value of $145,840.50. Following the sale, the chief financial officer now directly owns 8,757 shares in the company, valued at approximately $4,730,093.55. The trade was a 2.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark Brosius sold 492 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $554.17, for a total transaction of $272,651.64. Following the sale, the senior vice president now directly owns 3,072 shares in the company, valued at $1,702,410.24. This trade represents a 13.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,090 shares of company stock worth $7,496,119. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.